Scott Huennekens Named to Foldax’s Board of Directors

Foldax Inc. has welcomed a new member to its governing body.

Scott Huennekens has joined the firm’s Board of Directors as an independent member. He has more than 30 years of experience in the medical device industry leading high-profile companies through IPOs and acquisitions, and serving on the board of directors for several innovative startups.

“I am pleased to be joining the Foldax board. I believe Foldax is positioned to make the next significant advancement in heart valves since transcatheter valve replacement. My experience in leading innovative technologies on both the management and board sides can add value to Foldax’s commercialization efforts. I look forward to working with the board and management team to ensure the realization of Foldax’s potential,” said Huennekens.

Huennekens previously served as president and CEO of Verb Surgical, a robotics venture created by Google and J&J to revolutionize the future of surgery, which was subsequently wholly acquired by J&J. Prior to that, he led Volcano Corp., an innovator in catheter-based imaging for the heart, as its first and only president and CEO from startup to IPO to its sale to Philips. Earlier, as president and CEO of Digirad Corporation, a diagnostic imaging solutions provider, he led the company through an IPO. He currently serves on the board of directors for Nuvasive Inc., Acutus Medical Inc., KARDION GmbH, Proximie, Q’Apel Medical, Hyperfine, Envista Holdings, and Wondr Medical.

“We are delighted to welcome Scott to our board. He brings invaluable experience in several areas important for Foldax, including cardiovascular technology, robotics and business strategy. Importantly, Scott has been involved in several innovative ventures, such as Verb Surgical, which have had visionary missions to change the status quo—this is exactly what Foldax intends to do by transforming the heart valve space with its novel biopolymer valve,” said Foldax CEO Frank Maguire. 

Headquartered in Salt Lake City, Foldax develops surgical and transcatheter valves designed to last a lifetime. Foldax investors include Angel Physicians Fund, Biostar Capital, Caltech, Kairos Ventures, Memorial Care Innovation Fund, and Sayan Bioventures.
 
The Tria heart valve is considered investigational in the United States and is not available for commercial sale in America.